ALK and non-small cell lung carcinoma: It demonstrates that ALK-rearrangement may predict a favorable response to the therapy of bevacizumab combined with pemetrexed in advanced non-small cell lung cancer and this combination may be a reasonable choice for advanced ALK-rearrangement NSCLC patient when ALK-TKIs treatment failed.